Posts in Federal Circuit

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today affirming a district court ruling that Mylan Pharmaceuticals’ generic hypertension drug did not literally infringe Actelion Pharmaceuticals’ U.S. patents for its own hypertension drug, Veletri®. The CAFC also affirmed the district court’s holding that Actelion had not proven and was barred from asserting infringement by an equivalent.

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today affirming the dismissal of a pro se lawsuit brought by three inventors who contested the U.S. Patent and Trademark Office’s (USPTO) refusal to grant them reduced filing fees. The CAFC found that the inventors failed to adequately plead Article III standing, as their own representations to the USPTO undermined any claim of ownership in the disputed application.

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Monday affirmed a district court decision awarding attorney fees and costs to Nextremity Solutions, Inc. for an infringement suit brought against it by Extremity Medical, LLC, but denying attorney fees and costs for the successful parallel inter partes review proceeding (IPR) Nextremity pursued. The opinion was authored by Judge Lourie.

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today in Bissell, Inc. v. International Trade Commission, affirming a final determination of the International Trade Commission (ITC) that found no import violation by redesigned vacuum products. The CAFC affirmed the ITC’s refusal to grant an exclusion order and also agreed that the Commission properly determined that Bissel’s products satisfied the technical prong of the domestic industry requirement.

The U.S. Supreme Court has been asked to grant certiorari to resolve whether the Defend Trade Secrets Act (DTSA) permits an unjust enrichment award without any showing of actual loss resulting from the defendant’s misappropriation of trade secrets. The defendant in Tata Consultancy Services Ltd. v. Computer Sciences Corp. has petitioned for certiorari, arguing that actual loss is a prerequisite for an unjust enrichment award. The petition challenges a Fifth Circuit decision affirming a $56 million unjust enrichment award and a $112 million punitive award in favor of Computer Sciences Corp. (“CSC”), measured by the costs Tata Consultancy Services (TCS) avoided through its trade secret theft rather than by any proven actual loss to CSC.

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today in DK Crown Holdings Inc. v. AG 18, LLC, affirming a final written decision of the Patent Trial and Appeal Board (PTAB) and holding that DK Crown Holdings Inc., formerly known as DraftKings, Inc. (DK), failed to prove that claim 18 of U.S. Patent No. 9,978,205 was unpatentable during inter partes review (IPR).

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today in TJTM Technologies, LLC v. Google LLC, affirming the U.S. District Court for the Northern District of California’s dismissal of a patent infringement lawsuit and holding that the asserted patent claims are directed to patent-ineligible subject matter under 35 U.S.C. § 101. The nonprecedential decision was authored by Judge Chen and joined by Judges Dyk and Stark.

A person recently approached me at church with excitement regarding a software process he developed. His company was so pleased with the result that it is filing a patent, listing him as the inventor. This person knew that I had some kind of patent backstory, so he asked for my thoughts. My name is Jeffrey A. Killian, and I am the patent applicant in the Federal Circuit Court case # 2021 -2113 (In Re: Killian). I took no pleasure in telling my  friend at church that his patent application will be rejected. Plus, the official notice will have my precedential case quoted all over his rejection. With friends at church like me, who needs enemies? 

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Monday in a precedential decision authored by Judge Lourie affirmed a district court’s ruling determining certain claims of Enviro Tech Chemical Services, Inc.’s patent for a method of poultry treatment indefinite. Enviro Tech’s U.S. Patent No.10,912,321is titled “Methods of Using Peracetic Acid to Treat Poultry in a Chill Tank During Processing.” Enviro Tech sued Safe Foods Corp. for infringement of a number of claims of the patent in the U.S. District Court for the Eastern District of Arkansas.

The Supreme Court heard oral arguments yesterday in Hikma Pharmaceuticals USA v. Amarin Pharma, Inc., a case with broad implications for the generic industry’s practice of “skinny labeling” and the induced infringement standard for patent law and beyond. IPWatchdog reached out to members of the IP community for their initial takeaways from yesterday’s arguments.

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Wednesday in Federal Express Corporation v. Qualcomm Incorporated, vacating a determination by the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) that certain claims of a Federal Express Corporation patent were unpatentable as obvious. The CAFC also held that it could not review the PTAB’s refusal to determine whether all real parties in interest were identified in the petition for inter partes review (IPR).

The U.S. Supreme Court heard oral arguments today in Hikma v. Amarin, a closely-watched case that in part asks the Justices to weigh in on whether a drugmaker calling its product a “generic version” while citing public sales information about the branded drug induces infringement of a patented use fully carved out by the generic’s label. Hikma’s petition also asks whether a complaint states an induced infringement claim if it fails to allege any instruction or statement by the defendant mentioning the patented use. While some Justices today questioned why the case was even before them, others seemed concerned about the potential impact of the case for the generic pharmaceutical industry.

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today in Constellation Designs, LLC v. LG Electronics Inc., vacating in part and affirming in part a decision of the United States District Court for the Eastern District of Texas. The CAFC determined that the district court incorrectly found the “optimization claims” of Constellation Designs, LLC’s patents directed to eligible subject matter under 35 U.S.C. § 101, but correctly found the “constellation claims” eligible.

Pharmaceutical patent litigators are no strangers to the delicate dance between the Hatch-Waxman Act and 35 U.S.C. § 271(b). On one side of this statutory tightrope lies the Hatch-Waxman Act’s Section VIII pathway, which was designed to expedite affordable generic competition by allowing manufacturers to seek Food and Drug Administration (FDA) approval solely for unpatented indications—the proverbial “skinny label.” On the flip side lies Section 271(b), which imposes strict liability on anyone who “actively induces” patent infringement.